RATIONALE: Evidence from animal and human studies suggests that opiate drugs decrease emotional responses to negative stimuli and increase responses to positive stimuli. Such emotional effects may motivate misuse of oxycodone (OXY), a widely abused opiate. Yet, we know little about how OXY affects neural circuits underlying emotional processing in humans. OBJECTIVE: We examined effects of OXY on brain activity during presentation of positive and negative visual emotional stimuli. We predicted that OXY would decrease amygdala activity to negative stimuli and increase ventral striatum (VS) activity to positive stimuli. Secondarily, we examined the effects of OXY on other emotional network regions on an exploratory basis. METHODS: In a three-session study, healthy adults (N = 17) receivedplacebo, 10 and 20 mg OXY under counterbalanced, double-blind conditions. At each session, participants completed subjective and cardiovascular measures and underwent functional MRI (fMRI) scanning while completing two emotional response tasks. RESULTS: Our emotional tasks reliably activated emotional network areas. OXY produced subjective effects but did not alter either behavioral responses to emotional stimuli or activity in our primary areas of interest. OXY did decrease right medial orbitofrontal cortex (MOFC) responses to happy faces. CONCLUSIONS: Contrary to our expectations, OXY did not affect behavioral or neural responses to emotional stimuli in our primary areas of interest. Further, the effects of OXY in the MOFC would be more consistent with a decrease in value for happy faces. This may indicate that healthy adults do not receive emotional benefits from opiates, or the pharmacological actions of OXY differ from other opiates.
RCT Entities:
RATIONALE: Evidence from animal and human studies suggests that opiate drugs decrease emotional responses to negative stimuli and increase responses to positive stimuli. Such emotional effects may motivate misuse of oxycodone (OXY), a widely abused opiate. Yet, we know little about how OXY affects neural circuits underlying emotional processing in humans. OBJECTIVE: We examined effects of OXY on brain activity during presentation of positive and negative visual emotional stimuli. We predicted that OXY would decrease amygdala activity to negative stimuli and increase ventral striatum (VS) activity to positive stimuli. Secondarily, we examined the effects of OXY on other emotional network regions on an exploratory basis. METHODS: In a three-session study, healthy adults (N = 17) received placebo, 10 and 20 mg OXY under counterbalanced, double-blind conditions. At each session, participants completed subjective and cardiovascular measures and underwent functional MRI (fMRI) scanning while completing two emotional response tasks. RESULTS: Our emotional tasks reliably activated emotional network areas. OXY produced subjective effects but did not alter either behavioral responses to emotional stimuli or activity in our primary areas of interest. OXY did decrease right medial orbitofrontal cortex (MOFC) responses to happy faces. CONCLUSIONS: Contrary to our expectations, OXY did not affect behavioral or neural responses to emotional stimuli in our primary areas of interest. Further, the effects of OXY in the MOFC would be more consistent with a decrease in value for happy faces. This may indicate that healthy adults do not receive emotional benefits from opiates, or the pharmacological actions of OXY differ from other opiates.
Authors: Mika Leppä; Antti Korvenoja; Synnöve Carlson; Paula Timonen; Sami Martinkauppi; Jouni Ahonen; Per H Rosenberg; Hannu J Aronen; Eija Kalso Journal: Neuroimage Date: 2006-02-03 Impact factor: 6.556
Authors: Jaymin Upadhyay; Julie Anderson; Richard Baumgartner; Alexandre Coimbra; Adam J Schwarz; Gautam Pendse; Diana Wallin; Lauren Nutile; James Bishop; Edward George; Igor Elman; Soujanya Sunkaraneni; Gary Maier; Smriti Iyengar; Jeffrey L Evelhoch; David Bleakman; Richard Hargreaves; Lino Becerra; David Borsook Journal: Neuroimage Date: 2011-11-18 Impact factor: 6.556
Authors: Klaus J Wagner; Till Sprenger; Eberhard F Kochs; Thomas R Tölle; Michael Valet; Frode Willoch Journal: Anesthesiology Date: 2007-03 Impact factor: 7.892
Authors: Jonathan C Ipser; David Terburg; Supriya Syal; Nicole Phillips; Mark Solms; Jaak Panksepp; Susan Malcolm-Smith; Kevin Thomas; Dan J Stein; Jack van Honk Journal: Psychoneuroendocrinology Date: 2012-05-30 Impact factor: 4.905
Authors: Patrick M Beardsley; Mario D Aceto; Charles D Cook; Edward R Bowman; Jennifer L Newman; Louis S Harris Journal: Exp Clin Psychopharmacol Date: 2004-08 Impact factor: 3.157
Authors: Sarah L Withey; Lei Cao; Fernando B de Moura; Kenroy R Cayetano; Michael L Rohan; Jack Bergman; Stephen J Kohut Journal: Brain Imaging Behav Date: 2022-02-28 Impact factor: 3.224
Authors: Hestia Moningka; Sarah Lichenstein; Patrick D Worhunsky; Elise E DeVito; Dustin Scheinost; Sarah W Yip Journal: Neuropsychopharmacology Date: 2018-10-03 Impact factor: 7.853